The estimated Net Worth of Martin Shkreli is at least $14.9 Milion dollars as of 14 November 2014. Martin Shkreli owns over 1,172,000 units of Retrophin stock worth over $123,562 and over the last 12 years Martin sold RTRX stock worth over $14,790,416.
Sign up
Martin Shkreli RTRX stock SEC Form 4 insiders trading
Martin has made over 34 trades of the Retrophin stock since 2012, according to the Form 4 filled with the SEC. Most recently Martin sold 1,172,000 units of RTRX stock worth $10,360,480 on 14 November 2014.
The largest trade Martin's ever made was selling 1,172,000 units of Retrophin stock on 14 November 2014 worth over $10,360,480. On average, Martin trades about 63,484 units every 19 days since 2012. As of 14 November 2014 Martin still owns at least 1,765,168 units of Retrophin stock.
You can see the complete history of Martin Shkreli stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Martin Shkreli's mailing address?
Martin's mailing address filed with the SEC is 777 THIRD AVENUE, 22ND FLOOR, , NEW YORK, NY, 10017.
Insiders trading at Retrophin
Over the last 12 years, insiders at Retrophin have traded over $26,547,782 worth of Retrophin stock and bought 585,006 units worth $5,991,663 . The most active insiders traders include Martin Shkreli, Ron Squarer oraz Steve Aselage. On average, Retrophin executives and independent directors trade stock every 23 days with the average trade being worth of $1,651. The most recent stock trade was executed by Laura Clague on 23 November 2020, trading 7,500 units of RTRX stock currently worth $174,675.
What does Retrophin do?
Retrophin, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.
What does Retrophin's logo look like?
Complete history of Martin Shkreli stock trades at Retrophin
Retrophin executives and stock owners
Retrophin executives and other stock owners filed with the SEC include:
-
Eric Dube,
President, Chief Executive Officer, Director -
Elizabeth Reed,
Senior Vice President, General Counsel and Corporate Secretary -
Noah Rosenberg,
Chief Medical Officer -
Peter Heerma,
Chief Commercial Officer -
William Rote,
Senior Vice President and Head of Research and Development -
Laura Clague,
Chief Financial Officer, Senior Vice President -
Stephen Aselage,
Director -
Sandra Poole,
Independent Director -
Gary Lyons,
Independent Chairman of the Board -
Timothy Coughlin,
Independent Director -
Jeffrey Meckler,
Independent Director -
John Orwin,
Independent Director -
Roy Baynes,
Independent Director -
Ron Squarer,
Independent Director -
Suzanne Bruhn,
Independent Director -
Neil F. Mc Farlane,
Chief Operating Officer -
Jensen Margaret E Valeur,
General Counsel -
John W Kozarich,
Director -
Alvin Shih,
EVP of Research & Development -
Cornelius E Golding,
Director -
Steve Aselage,
Director -
Martin Shkreli,
Chief Executive Officer -
Steven Gary Richardson,
Director -
Horacio Plotkin,
Chief Medical Officer -
Jeffrey Paley,
Director -
Marc L Panoff,
Chief Financial Officer